Risk Evaluation and Mitigation Strategy (REMS) Assessment Protocol - Zydelig (idelalisib) tablets (Zydelig REMS KAB)

First published 10/11/2015

Last updated 02/07/2024

EU PAS number:

EUPAS11551

Study

Finalised

Download as PDF

Documents

Study protocol

Initial protocol

Zydelig_REMS HCP Protocol

English (662.46 KB - PDF)View document

Study results

Study report

Other information

ENCePP Seal

ENCePP Seal documents